The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL).
 
Fateeha Furqan
No Relationships to Disclose
 
Michael Hemmer
Employment - Kite, a Gilead Company
 
Michael Tees
Research Funding - 2seventy (Inst); Accutar Biotech (Inst); Allogene Therapeutics (Inst); Cargo (Inst); Juno Therapeutics (Inst); Kite Therapeutics (Inst); Merck (Inst); Nkarta (Inst); Step Pharma (Inst)
 
John Baird
Honoraria - Curio Science; Olson Research Group
Consulting or Advisory Role - Gerson Lehrman Group
Speakers' Bureau - Kite/Gilead
Research Funding - Genentech/Roche (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Regeneron (Inst)
 
Jennifer Holter-Chakrabarty
Research Funding - Abbvie; ORCA Therapeutics
 
Brian McClune
No Relationships to Disclose
 
Caron Jacobson
Honoraria - Abbvie; ADC Therapeutics; Aleta Biotherapeutics; Appia Bio; AstraZeneca; Bristol-Myers Squibb; Caribou Biosciences; Janssen; Kite/Gilead; Kyverna Therapeutics; Miltenyi Biomedicine; Novartis; Sana; Synthekine
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Aleta Biotherapeutics; Appia Bio; AstraZeneca; Bristol-Myers Squibb; Janssen; Kite/Gilead; Kyverna Therapeutics; Miltenyi Biomedicine; Novartis; Sana; Synthekine
Research Funding - Kite, a Gilead company
 
Saurabh Dahiya
Consulting or Advisory Role - Adaptive Biotechnologies; Bristol Myers Squibb; Kite/Gilead
 
Frederick Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Jiali Yan
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Jenny Kim
Employment - Kite, a Gilead Company
 
Elena Pizzi
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Biomarin; Kite, a Gilead Company
 
Dafna Bonneh-Barkay
Employment - Kite, a Gilead Company
Other Relationship - Kite, a Gilead Company
 
Hil Hsu
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Amgen; Kite, a Gilead Company
 
Waleska Perez
No Relationships to Disclose
 
Zhongyu Feng
No Relationships to Disclose
 
Marcelo Pasquini
Honoraria - Celgene; Gilead Sciences
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Medigene (Inst); Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Kite/Gilead (Inst); Novartis (Inst)
 
Yi Lin
Consulting or Advisory Role - Adicet Bio (Inst); Bristol-Myers Squibb (Inst); Caribou Biosciences (Inst); Chimeric Therapeutics (Inst); Fosun Kite (Inst); Genentech (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Nektar (Inst); NexImmune (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Tessera (Inst); Vineti (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Janssen Oncology (Inst)